Background
Birth of the Hygiene Hypothesis (HH)
Epidemiological evidence
Pathophysiology of the Hygiene Hypothesis (HH)
Who are the actors in the HH?
Evolution of our microbial environment in the Western world
An example of immunomodulation by infectious agents: about helminthes
Th1 and Th2 cells
Dendritic cells
B-regulatory cells
Innate immune cells
Microbiota regulation
Proof of concept of the HH: helminth therapy
Inflammatory bowel disease
| Mice | Attenuates DNBS-induced colitis | |
↑ IL-4, IL-13, TGF-β and ↓ IFN-γ, IL-1β, MPO activity, iNOS expression | |||
Prevents or attenuates TNBS- and DSS-induced colitis | |||
↑ IL-4, IL-10, F4/80+ macrophages and ↓ IFN-γ | |||
Prevents Rag IL-10−/− T-cell transfer model of colitis | |||
↑ tolerogenic DC and ↓ IFN-γ, IL-17 | |||
Attenuates DNBS-induced colitis | |||
↑ IL-10 | |||
Schistosoma japonicum [146] | Attenuates TNBS-induced colitis | ||
↑ IL-4, IL-5, IL-13, Treg, and ↓ IFN-γ | |||
Clonorchis sinensis [135] | Attenuates DSS-induced colitis | ||
↑ IL-10, IL-10+ F4/80+ macrophages and ↓ TNF-α | |||
Human | CD: open-label study: 79.3% responded, 72.4% remitted at 24 weeks | ||
UC: placebo-controlled trial: 43.3% responded 12 weeks versus 16.7% in placebo group; no significant difference in remission rates | |||
CD: phase 2 TRUST-I trial: no significant differences between TSO and placebo groups | |||
Necator americanus [155] | Improvement CDAI in 5/9 patients at 20 weeks and 3/5 at 45 weeks | ||
Mild adverse events | |||
Multiple sclerosis
| Mice | Reduces incidence and attenuates EAE | |
↑ IL-4, IL-10, TGF-β and ↓ IFN-γ, TNF-α, IL-12, and CNS inflammatory cell infiltration | |||
Attenuates EAE | |||
↑ IL-4, IL-10, TGF-β, Treg, tolerogenic DC and ↓ IFN-γ, IL-17 | |||
H. polygyrus [129] | Prevents EAE by transfer of B-cells from IL-10−/− infected mice | ||
Trichinella pseudospiralis [106] | Delays and attenuates EAE ↑ IL-4, IL-5, IL-10 and ↓ TNF-α, IFN-γ, IL-1β, IL-6, IL-17 | ||
Schistosoma japonicum [164] | Attenuates EAE | ||
↑ IL-4 and ↓ IFN-γ and CNS inflammation | |||
Fasciola hepatica [161] | Attenuates EAE ↑ IL-10, tolerogenic DC, M2-macrophages, IL-10 secreting T-cells and ↓ IFN-γ, IL-17 | ||
Taenia Crassiceps [159] | Attenuates EAE | ||
↑ IL-4, IL-10, M2-macrophages and ↓ TNF-α, IL-17, iNOS expression and CNS inflammation | |||
Human | 12 naturally infected MS patients and 12 controls, follow-up 7.5 years | ||
↓ relapses, disability scores, MRI activity, and ↑ IL-10, TGF-β, Treg, Breg and ↓ IFN-γ, IL-12 in infected patients | |||
Anti-helminthic treatment ↑ clinical and radiological activity | |||
TSO [167] | 5 patients with relapsing-remitting MS | ||
↓ mean number of new MRI lesions | |||
Rheumatoid arthritis
| Mice | Reduces incidence and attenuates CIA | |
↑ IL-10, late IL-22, tolerogenic DC, Breg and ↓ TNF-α, IFN-γ, IL-6, IL-17, early IL-22, IgG2a | |||
Immunomodulatory effects related to PC moiety | |||
Schistosoma mansoni [107] | Attenuates CIA | ||
↑ IL-4, IL-10 and ↓ TNF-α, IFN-γ, IL-1β, IL-6, IL-17A, IgG2a | |||
Hymenoleptis diminuta [174] | Attenuates Freund’s complete adjuvant-induced arthritis | ||
Protection abrogated in mice lacking T- and B-cells or IL-4Rα or IL-10 | |||
Fasciola.hepatica [175] | Reduces incidence and attenuates CIA | ||
↑ IL-10, TGF-β, tolerogenic DC, Treg and ↓ TNF-α, IL-17A, IgG2a | |||
Schistosoma japonicum [176] | Attenuates CIA | ||
↑ IL-10, Treg, IgG1 and ↓ TNF-α, IFN-γ, IL-1β, IL-6 Th-17 cells, IgG2a | |||
Reduces incidence and attenuates spontaneous arthritis in MRL/lpr mice | |||
↑ IL-4, IgG1 | |||
Type-1 diabetes
| Mice | Reduces incidence or prevents diabetes in NOD mice | |
↑ IL-4, IL-5, IL-10, IL-13, TGF-β, tolerogenic DC, Treg, V alpha 14i NKT cells | |||
Prevents class switch from IgM to IgG anti-insulin autoantibodies | |||
ω1 glycoprotein secreted by S. mansoni ova responsible for its effects | |||
Prevents and reduces severity of diabetes in NOD mice | |||
↑ IL-4, IL-10, IL-13, Treg and ↓ pancreatic insulitis | |||
Trichinella spiralis [109] | Prevents diabetes in NOD mice | ||
↑ IL-4 and ↓ pancreatic insulitis. No change in IL-10 and IFN-γ | |||
Prevents diabetes in immunocompetent and IL-4 deficient NOD mice | |||
↑ IL-4, IL-5, IgG1, Treg and ↓ pancreatic insulitis | |||
Dirofilaria immitis [181] | Prevents diabetes in NOD mice | ||
↑ IgE. Prevents class switch from IgM to IgG anti-insulin autoantibodies | |||
Celiac disease
| Human | No significant change in symptom severity at the gluten challenge following treatment | |
↓ IFN-γ, IL17A | |||
Systemic lupus erythematosus
| Mice | Schistosoma mansoni [185] | Change glomerulonephritis phenotype from diffuse proliferative to membranous pattern |
↑ IL-4, IL-5, IL-10, and TGF-β | |||
Graves’ disease
| Mice | Schistosoma mansoni [186] | Prevent Grave’s disease development |
↓ IFN-γ, IgG2a, anti-TSHR antibodies | |||
Psoriasis
| Mice | Schistosoma mansoni [187] | Prevent psoriatic skin lesions in fsn/fsn mice |
↑ IL-13 and ↓ IFN-γ |